HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Sep
20
VOLUNTARY ANNOUNCEMENT - "LENALIDOMIDE CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Sep
09
VOLUNTARY ANNOUNCEMENT - "TG103 INJECTION" OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
Sep
09
VOLUNTARY ANNOUNCEMENT - "TG103 INJECTION" OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Aug
24
2022 INTERIM DIVIDEND
Aug
24
2022 INTERIM RESULTS ANNOUNCEMENT
Aug
23
VOLUNTARY ANNOUNCEMENT - UPDATE ON THE CLINICAL STUDY PROGRESS OF SARS-CoV-2 mRNA VACCINE (SYS6006)
Aug
23
VOLUNTARY ANNOUNCEMENT - COMPLETION OF A CLINICAL STUDY OF HETEROLOGOUS BOOSTER IMMUNIZATION OF SARS-CoV-2 mRNA VACCINE (SYS6006)
Aug
22
VOLUNTARY ANNOUNCEMENT - SELECTIVE NTRK AND ROS1 DUAL INHIBITOR "SYHX2009" OBTAINS CLINICAL TRIAL APPROVAL
Aug
22
VOLUNTARY ANNOUNCEMENT - CLASS 1 NEW DRUG "PRUSOGLIPTIN TABLETS" MEETS PREDEFINED ENDPOINTS IN THE PIVOTAL CLINICAL TRIALS FOR THE TREATMENT OF TYPE 2 DIABETES
Aug
19
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE HALF YEAR ENDED 30 JUNE 2022
Aug
19
VOLUNTARY ANNOUNCEMENT - "MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Aug
18
VOLUNTARY ANNOUNCEMENT - DUOENDA (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS
Aug
12
DATE OF BOARD MEETING
Aug
04
VOLUNTARY ANNOUNCEMENT - MINGFULE (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) MET PRIMARY ENDPOINT IN PHASE III STUDY FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
Aug
04
CHANGE OF ADDRESS OF SHARE REGISTRAR AND TRANSFER OFFICE
Aug
01
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Aug
01
RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR
Jul
28
VOLUNTARY ANNOUNCEMENT - DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF GASTRIC CANCER
Jul
28
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYSA1801 WITH ELEVATION ONCOLOGY, INC.
Jul
11
VOLUNTARY ANNOUNCEMENT - "LACOSAMIDE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Jul
11
VOLUNTARY ANNOUNCEMENT - "GABAPENTIN CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Jun
24
CONNECTED TRANSACTIONS - LEASE AGREEMENTS
Jun
22
VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR JMT103 ACCEPTED BY THE NMPA
Jun
13
VOLUNTARY ANNOUNCEMENT - "PRAMIPEXOLE DIHYDROCHLORIDE SUSTAINED-RELEASE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
May
30
VOLUNTARY ANNOUNCEMENT - "TENOFOVIR ALAFENAMIDE FUMARATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
May
27
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
May
27
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF CHIEF EXECUTIVE OFFICER
May
26
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 26 MAY 2022
May
25
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2022
May
18
VOLUNTARY ANNOUNCEMENT - "DOXOFYLLINE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
May
13
DATE OF BOARD MEETING
May
05
VOLUNTARY ANNOUNCEMENT - "DONEPEZIL HYDROCHLORIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Apr
28
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2022
Apr
26
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE FGFR4 INHIBITOR "SYHX2005" OBTAINS CLINICAL TRIAL APPROVAL
Apr
22
VOLUNTARY ANNOUNCEMENT - "ESOMEPRAZOLE SODIUM FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Apr
22
VOLUNTARY ANNOUNCEMENT - "VORTIOXETINE HYDROBROMIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Apr
22
VOLUNTARY ANNOUNCEMENT - "NIFEDIPINE CONTROLLED-RELEASE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Apr
21
NOTICE OF ANNUAL GENERAL MEETING
Apr
20
VOLUNTARY ANNOUNCEMENT - ANTI-TUMOR NANODRUG "CISPLATIN MICELLE INJECTION" OBTAINS CLINICAL TRIAL APPROVAL
Apr
03
VOLUNTARY ANNOUNCEMENT - COVID-19 mRNA VACCINE "SYS6006" OBTAINS CLINICAL TRIAL APPROVAL
Mar
22
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
22
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021
Mar
21
VOLUNTARY ANNOUNCEMENT - CLASS 1 NEW DRUG JMT103 MEETS PRE-DEFINED ENDPOINTS IN THE PIVOTAL CLINICAL TRIAL FOR THE TREATMENT OF UNRESECTABLE OR SURGICALLY DIFFICULT GIANT CELL TUMOR OF BONE
Mar
18
VOLUNTARY ANNOUNCEMENT - "DUVELISIB CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Mar
17
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2021
Mar
10
DATE OF BOARD MEETING
Feb
08
VOLUNTARY ANNOUNCEMENT - ACQUISITION OF EQUITY INTEREST IN RECOMGEN BIOTECH
Feb
07
VOLUNTARY ANNOUNCEMENT - ANTI-TUMOR NANODRUG "SYHA1908 FOR INJECTION" OBTAINS CLINICAL TRIAL APPROVAL
Jan
27
VOLUNTARY ANNOUNCEMENT - JMT601 (CPO107) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Jan
20
VOLUNTARY ANNOUNCEMENT - GRANT OF SHARE AWARDS TO SELECTED GRANTEES BY A SHAREHOLDER
Jan
12
VOLUNTARY ANNOUNCEMENT - "LENVATINIB MESILATE CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Jan
11
VOLUNTARY ANNOUNCEMENT - "MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Jan
10
VOLUNTARY ANNOUNCEMENT - "ZOLEDRONIC ACID INJECTION" OBTAINS DRUG REGISTRATION APPROVAL

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2022 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer